Muromonab-cd3

Drug #2006

Muromonab-CD3 is a monoclonal antibody (mAb), also known as Orthoclone OKT3 . It is a mouse-derived (murine) monoclonal antibody that specifically binds to the CD3 (T3) protein found on the surface of T cells. It is an intravenous drug, used for the prevention and treatment of transplant rejection.

← Previous drug Next drug →

Primary Characteristics

It is of Natural origin and belongs to Moco-clonal antibody murine.

Molecular Weight: 150000 · Non-proprietary name: Muromonab-cd3.

Pharmacokinetics

None recorded.

Indications

Muromonab-cd3 is primarily indicated in conditions like Graft rejection, Graft versus host disease.

Contraindications

Muromonab-cd3 is contraindicated in conditions like Hypertension, Fever, Hypersensitivity to the drug.

Dosage

Muromonab-cd3's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
5 mg	5 mg	—	IV	Once a day injected in vein for 10-14 days.
Paediatric Dosage (20kg)
5 mg	5 mg	—	IV	IV Injection for 10-14 days due to higher CD3 lymphocytes count the dose required to be titrated upw
Neonatal Dosage (3kg)
No data.

Drug Interactions

3 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Muromonab-cd3 are Hypotension, Pulmonary edema , Convulsions , Seizures, Tachycardia, Hallucinations , Cardiac arrest, Trembling , Bruising.

Muromonab-cd3 is known to cause more or less tolerable side effects which are usually transient. These include Chills, Diarrhea, Dizziness, faintness, Fever, GI bleeding, Headache, Nausea and vomiting, Oedema, Rigors , Tremor.

Warnings / Precautions

Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present. Patient temperature should not exceed 37.8°C (100°F) at time of administration. Severe pulmonary edema has occurred in patients with fluid overload. May result in an increased susceptibility to infection; dosage of concomitant immunosuppressants should be reduced during Muromonab-cd3 therapy; cyclosporine should be decreased to 50% usual maintenance dose and maintenance therapy resumed about 4 days before stopping Muromonab-cd3.

Available Brands

None recorded.

Drug Classification

1.8.1 — Immunomodulators